All In Biotech

Drug Trial Radar · NCT06399185

Effect of Dexmedetomidine and Esketamine on Catheter-related Bladder Discomfort

Effect of Dexmedetomidine and Esketamine on Catheter-related Bladder Discomfort in Patients Undergoing Transurethral Surgery: a 2 x 2 Factorial Randomized Trial

Last checked: Nov 20, 2026Latest source record: Jul 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 1,740 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,740

Planned (sponsor's estimate)

Start

Jun 6, 2024

Primary completion

Apr 2027

Study completion May 2027

Sponsor

Lead sponsor
Peking University First HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Peking University Shenzhen Hospital
First posted
May 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Factorial
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Catheter-related bladder discomfort (CRBD) is common in patients awaking from general anesthesia with an urinary catheter. We suppose that that use of dexmedetomidine and/or esketamine during anesthesia may reduce the occurrence of CRBD. This 2x2 factorial randomized trial is designed to explore the effects of esketamine, dexmedetomidine, and their combination on the occurrence CRBD in patients undergoing transurethral urological surgery.

Conditions

  • Urinary Catheter
  • Catheter-related Bladder Discomfort
  • Dexmedetomidine
  • Esketamine

Interventions

  • Normal salineDrug

    20 ml of normal saline is infused intravenously at 80 ml/h after anesthesia induction but before surgery.

  • DexmedetomidineDrug

    Dexmedetomidine 0.5 μg/kg, diluted with normal salinet o 20 ml, is infused intravenously at 60 ml/h after anesthesia induction but before surgery.

  • EsketamineDrug

    Esketamine 0.25 mg/kg, diluted with normal saline to 20 ml, is infused intravenously at 80 ml/h after anesthesia induction but before surgery.

  • Combined dexmedetomidine-esketamineDrug

    Dexmedetomidine 0.5 μg/kg and esketamine 0.25 mg/kg, diluted with normal saline to 20 ml, is infused intravenously at 80 ml/h after anesthesia induction but before surgery.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of catheter-related bladder discomfort (CRBD) within 24 hours after surgery.Time frame: Up to 24 hours after surgery.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Peking University Shenzhen Hospital

    Shenzhen, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.